Beranda › Kanker Kandung Empedu
Uji klinis Kanker Kandung Empedu yang merekrut di AS
14 studi untuk Kanker Kandung Empedu merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Nashville, TN4 studi
- New York City, NY4 studi
- Cleveland, OH4 studi
- Baldwin Park, CA4 studi
- Pittsburgh, PA3 studi
- Seattle, WA3 studi
- Portland, OR3 studi
- Detroit, MI3 studi
- Los Angeles, CA3 studi
- Oklahoma City, OK3 studi
- Dallas, TX3 studi
- Houston, TX3 studi
- Omaha, NE3 studi
- Philadelphia, PA3 studi
- Boston, MA3 studi
- Louisville, KY3 studi
- Birmingham, AL3 studi
Berdasarkan negara bagian
- Alabama3 studi
- California9 studi
- Colorado4 studi
- Connecticut3 studi
- Florida8 studi
- Illinois4 studi
- Kentucky3 studi
- Massachusetts4 studi
- Michigan4 studi
- Minnesota3 studi
- Nebraska3 studi
- New York5 studi
- North Carolina4 studi
- Ohio7 studi
- Oklahoma3 studi
- Oregon3 studi
- Pennsylvania4 studi
- Tennessee4 studi
- Texas5 studi
- Washington3 studi
- Wisconsin3 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07265674A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07221253DESTINY-PANTUMOUR04
Menerima pesertaStudi observasional
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Menerima pesertaFase 2
Usia 19 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07146646The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT04585750Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06282575Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07780838A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06760819Distance-Based Exercise to Preserve Function and Prevent Disability
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07059884Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT05285358Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Menerima pesertaFase 1/2
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT05000294Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT06101277Integrated Cancer Repository for Cancer Research
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Menerima peserta
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 20 Feb 2026 · NCT04907643Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.